ReviewFrontiers in immunology2022
Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Migrasome-transported PTGES amplifies the PGE2 cascade in SPP1Nature communications · 2026Article
- Transcriptomic atlas of premalignant oral squamous cell carcinoma in an aging mouse model reveals an enhanced immune response and dysregulation of head and neck tissue stem cells.bioRxiv : the preprint server for biology · 2026Article
- Article
- Review
- Heterogeneous mechanisms, risk stratification, and translational advances in the malignant transformation of oral potentially malignant disorders to oral squamous cell carcinoma.Frontiers in molecular biosciences · 2026Review
- The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy.International journal of nanomedicine · 2026Review
- Salivary MicroRNAs as Innovative Biomarkers for Diagnosis and Prediction of the Oral Potentially Malignant Disorders Transition Towards Oral Cancer: A Systematic Review.Journal of clinical medicine · 2025Review
- Article
- Distant metastasis of oral squamous cell carcinoma: immune escape mechanism and new perspectives on treatment.Discover oncology · 2025Review
- A novel AI-based score for assessing the prognostic value of intra-epithelial lymphocytes in oral epithelial dysplasia.British journal of cancer · 2025Article
- Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service.Head & neck · 2025Review
- Review
- Identification and Verification of a Prognostic Risk Signature in Oral Squamous Cell Carcinoma.Current topics in medicinal chemistry · 2025Article
- Oral Pre-malignancy: An Update on Novel Therapeutic Approaches.Current oncology reports · 2024Review
- TIME for Bugs: The Immune Microenvironment and Microbes in Precancer.Cancer prevention research (Philadelphia, Pa.) · 2023Review
- Article
- Review
- Precancerous Lesions of the Head and Neck Region and Their Stromal Aberrations: Piecemeal Data.Cancers · 2023Review
- CC chemokine receptor 7 promotes macrophage recruitment and induces M2-polarization through CC chemokine ligand 19&21 in oral squamous cell carcinoma.Discover oncology · 2022Article
- Type-2 epithelial-mesenchymal transition in oral mucosal nonneoplastic diseases.Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
Oral premalignant lesions (OPLs) are the precursors to oral cavity cancers, and have variable rates of progression to invasive disease. As an intermediate state, OPLs have acquired a subset of the genomic alterations while arising in an oral inflammatory environment. These specific genomic changes may facilitate the transition to an immune microenvironment that permits malignant transformation. Here, we will discuss mechanisms by which OPLs develop an immunosuppressive microenvironment that facilitates progression to invasive cancer. We will describe how genomic alterations and immune microenvironmental changes co-evolve and cooperate to promote OSCC progression. Finally, we will describe how these immune microenvironmental changes provide specific and unique evolutionary vulnerabilities for targeted therapies. Therefore, understanding the genomic changes that drive immunosuppressive microenvironments may eventually translate into novel biomarker and/or therapeutic approaches to limit the progression of OPLs to potential lethal oral cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.